US Patent Issued to Purdue Research Foundation on Sept. 1 for "Fibroblast activation protein (FAP)-targeted antifibrotic therapy" (Indiana Inventors)

ALEXANDRIA, Va., Sept. 1 -- United States Patent no. 12,721,898, issued on Sept. 1, was assigned to Purdue Research Foundation (West Lafayette, Ind.).

"Fibroblast activation protein (FAP)-targeted antifibrotic therapy" was invented by Philip Stewart Low (West Lafayette, Ind.), Spencer D. Lindeman (West Lafayette, Ind.) and Ramesh Mukkamala (West Lafayette, Ind.).

According to the abstract* released by the U.S. Patent & Trademark Office: "A compound of formula Fa-L-Ia (A) or Fa-Ia (B), wherein Fa is a fibroblast activation protein alpha (FAPAlpha) targeting moiety, L is a linker, and Ia is an inhibitor of a signaling pathway necessary for fibrosis in cancer-associated fibroblasts (CAFs); a pharmaceutical composition comprising same; and me...